Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study

Kim A. Papp, Mark G. Lebwohl, Diamant Thaçi, Janusz Jaworski, Bartlomiej Kwiek, Jakub Trefler, Anna Dudek, Jacek C. Szepietowski, Nataliya Reznichenko, Joanna Narbutt, Wojciech Baran, Joanna Kolinek, Stefan Daniluk, Katarzyna Bartnicka-Maslowska, Adam Reich, Yuriy Andrashko, Sunghyun Kim, Yunju Bae, Dabee Jeon, Jinsun Jung, Hyunseung Lee, Tina Pyo, Woori Ko

Open source

DOI: 10.1007/s40259-023-00630-5
Published: 2023-11-22
Container: BioDrugs
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s40259-023-00630-5,
  title = {Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study},
  author = {Kim A. Papp and Mark G. Lebwohl and Diamant Thaçi and Janusz Jaworski and Bartlomiej Kwiek and Jakub Trefler and Anna Dudek and Jacek C. Szepietowski and Nataliya Reznichenko and Joanna Narbutt and Wojciech Baran and Joanna Kolinek and Stefan Daniluk and Katarzyna Bartnicka-Maslowska and Adam Reich and Yuriy Andrashko and Sunghyun Kim and Yunju Bae and Dabee Jeon and Jinsun Jung and Hyunseung Lee and Tina Pyo and Woori Ko},
  year = {2023},
  journal = {BioDrugs},
  doi = {10.1007/s40259-023-00630-5},
  url = {https://doi.org/10.1007/s40259-023-00630-5}
}

RIS

TY  - JOUR
TI  - Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study
AU  - Kim A. Papp
AU  - Mark G. Lebwohl
AU  - Diamant Thaçi
AU  - Janusz Jaworski
AU  - Bartlomiej Kwiek
AU  - Jakub Trefler
AU  - Anna Dudek
AU  - Jacek C. Szepietowski
AU  - Nataliya Reznichenko
AU  - Joanna Narbutt
AU  - Wojciech Baran
AU  - Joanna Kolinek
AU  - Stefan Daniluk
AU  - Katarzyna Bartnicka-Maslowska
AU  - Adam Reich
AU  - Yuriy Andrashko
AU  - Sunghyun Kim
AU  - Yunju Bae
AU  - Dabee Jeon
AU  - Jinsun Jung
AU  - Hyunseung Lee
AU  - Tina Pyo
AU  - Woori Ko
PY  - 2023
JO  - BioDrugs
DO  - 10.1007/s40259-023-00630-5
UR  - https://doi.org/10.1007/s40259-023-00630-5
ER  -

APA

Papp, K. A., Lebwohl, M. G., Thaçi, D., Jaworski, J., Kwiek, B., Trefler, J., Dudek, A., Szepietowski, J. C., Reznichenko, N., Narbutt, J., Baran, W., Kolinek, J., Daniluk, S., Bartnicka-Maslowska, K., Reich, A., Andrashko, Y., Kim, S., Bae, Y., Jeon, D., Jung, J., Lee, H., Pyo, T., & Ko, W. (2023). Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study. BioDrugs. https://doi.org/10.1007/s40259-023-00630-5

Source records

crossref · retrieved 2026-09-26T22:41:38.161Z